D. E. Shaw & Co. Inc. Purchases 4,354 Shares of National Research Co. (NASDAQ:NRC)

D. E. Shaw & Co. Inc. lifted its position in shares of National Research Co. (NASDAQ:NRC) by 16.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,437 shares of the company’s stock after purchasing an additional 4,354 shares during the quarter. D. E. Shaw & Co. Inc. owned approximately 0.13% of National Research worth $555,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. grew its stake in shares of National Research by 8.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 17,194 shares of the company’s stock valued at $393,000 after purchasing an additional 1,373 shares during the period. Principal Financial Group Inc. boosted its stake in National Research by 10.7% in the 4th quarter. Principal Financial Group Inc. now owns 12,018 shares of the company’s stock valued at $212,000 after buying an additional 1,161 shares in the last quarter. MetLife Investment Management LLC grew its position in National Research by 28.7% in the fourth quarter. MetLife Investment Management LLC now owns 11,630 shares of the company’s stock valued at $205,000 after acquiring an additional 2,592 shares during the period. SG Americas Securities LLC raised its stake in National Research by 35.0% during the fourth quarter. SG Americas Securities LLC now owns 7,298 shares of the company’s stock worth $129,000 after acquiring an additional 1,893 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in National Research by 8.1% during the fourth quarter. American Century Companies Inc. now owns 39,254 shares of the company’s stock worth $692,000 after acquiring an additional 2,956 shares in the last quarter. 47.26% of the stock is currently owned by institutional investors.

National Research Stock Performance

NASDAQ:NRC opened at $13.59 on Monday. The stock has a market capitalization of $309.65 million, a P/E ratio of 12.94 and a beta of 0.34. The company has a current ratio of 0.47, a quick ratio of 0.47 and a debt-to-equity ratio of 1.30. National Research Co. has a 1 year low of $9.76 and a 1 year high of $30.79. The firm has a 50 day moving average of $12.54 and a 200-day moving average of $15.71.

National Research (NASDAQ:NRC) last announced its earnings results on Monday, April 28th. The company reported $0.25 earnings per share (EPS) for the quarter. National Research had a net margin of 17.32% and a return on equity of 66.52%. The company had revenue of $33.55 million for the quarter.

National Research Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 11th. Stockholders of record on Friday, June 27th will be paid a $0.12 dividend. The ex-dividend date is Friday, June 27th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 3.53%. National Research’s dividend payout ratio (DPR) is presently 46.60%.

Insider Activity at National Research

In other National Research news, major shareholder Patrick E. Beans acquired 2,500 shares of the business’s stock in a transaction dated Monday, May 12th. The shares were acquired at an average price of $13.59 per share, for a total transaction of $33,975.00. Following the acquisition, the insider now directly owns 35,003 shares of the company’s stock, valued at approximately $475,690.77. This trade represents a 7.69% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 8.10% of the stock is currently owned by corporate insiders.

National Research Company Profile

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.